|Bid||0.0000 x 1300|
|Ask||7.2200 x 3000|
|Day's Range||4.1100 - 4.4700|
|52 Week Range||3.5900 - 17.4000|
|Beta (3Y Monthly)||-0.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019 - May 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, ...
TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently evaluating investigational centers in the U.S. and expects to proceed with enrolling the first patient into its Phase 2b clinical trial in the current quarter. “We have completed the manufacturing of our active pharmaceutical ingredient and have the drug product for the first cohort ready to distribute to our investigational centers in the U.S.,” said Michael Brooks , President of Edesa.
Edesa Biotech (NASDAQ:EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).Source: Shutterstock The approval from the FDA is for Edesa Biotech to move forward with a study of EB01. This is a novel sPLA2 inhibitor that the company is working on. It hopes to use it to treat chronic allergic contact dermatitis.According to Edesa Biotech, this approval will allow it to start a Phase 2b clinical protocol and clinical investigation into the drug. The company says that it is planning to enroll the first patient in the study starting sometime next quarter.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S.," Dr. Par Nijhawan, CEO of Edesa Biotech, said in a statement. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01." * 6 Stocks Ready to Bounce on a Trade Deal Edesa Biotech says that it will be performing a randomized, double-blind, vehicle-controlled, sample size adaptive design study of the drug's ability to treat chronic allergic contact dermatitis. This will have patients using various EB01 creams with different strengths over a 28-day period. It also points out that the study may include up to 166 patients.EDSA stock was up 115% as of noon Thursday, but is down 26% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval appeared first on InvestorPlace.
Shares of Edesa Biotech Inc. shot up 140% in premarket trade after the Toronto-based company said the FDA had given it the go-ahead to start a Phase 2b trial looking at a topical treatment for chronic allergic contact dermatitis. The treatment, called EB01, is the company's lead drug candidate. "There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S.," said Par Nijhawan, Edesa's chief executive officer. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01." Shares of Edesa have declined 22.5% in the year to date through Wednesday, while the S&P 500 has gained 16.7%.
TORONTO , June 20, 2019 /CNW/ -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis. The FDA "safe to proceed" letter formally approves the company's Phase 2b clinical protocol and authorizes the company to begin its clinical investigation.